Tivantinib (ARQ197) in hepatocellular carcinoma

Camillo Porta, Palma Giglione, Alessandra Ferrari, Francesca Reversi, Wanda Liguigli, Ilaria Imarisio, Carlo Ganini

Research output: Contribution to journalArticlepeer-review


Here we review the development of tivantinib, a selective oral inhibitor of c-MET. The initially identified dose and schedule for clinical use was 360 mg twice daily. Biological considerations and early results suggested its activity against hepatocellular carcinoma after progression on sorafenib. The results of randomized Phase II study in this setting have already been reported; while in the overall population, the risk of progression was reduced by 36% (HR: 0.64; 90% CI: 0.43-0.94; p = 0.04), in the pre-defined MET-high population median overall survival (7.2 vs 3.8 months; p = 0.01), median time to progression (2.7 vs 1.4 months; p = 0.03) as well as disease control rate (50 vs 20%), were increased by tivantinib. During study conduction, tivantinib dose was amended to 240 mg twice daily, due to a high incidence of neutropenia, without losing clinical efficacy. Presently, a global Phase III trial is being conducted.

Original languageEnglish
Pages (from-to)615-622
Number of pages8
JournalExpert Review of Anticancer Therapy
Issue number6
Publication statusPublished - Jun 1 2015


  • development
  • hepatocellular carcinoma
  • MET inhibitor
  • tivantinib

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Tivantinib (ARQ197) in hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this